Table 1.
Demographics of the patients (n = 16)
| Value | |
|---|---|
| Transplantation date | 11/01-06/04 |
| Sex, no | M, 12; F, 4 |
| Age, y (range) | 65 (52-73) |
| Disease, no. | |
| High-risk MDS | 9 |
| Refractory AML | 4 |
| AL-CR2 | 2 |
| Resistant NHL | 1 |
| Preparative regimen, no. | |
| Flu/Cy | 5 |
| Flu/Mel | 5 |
| Flu/Bu | 6 |
| F-to-M transplanations, no. | 11 |
| CMV+ recipients, no. | 14 |
| Graft (range) | |
| CD34 dose, × 106/kg | 4.5 (3.4-7.3) |
| CD3 dose, × 108/kg | 1.0 (0.2-1.5) |
| Engraftment, d | |
| ANC more than 500/μL (range) | 13 (10-22) |
| Graft rejection (time) | 1 (day +24) |
| Day +30 donor chimerism, % (range) | |
| T cell | 100 (14-100) |
| Myeloid | 100 (4-100) |
MDS indicates myelodysplastic syndrome; AML, acute myelogenous leukemia; AL, acute leukemia; CR, complete remission; NHL, non-Hodgkin lymphoma; Flu, fludarabine; Cy, cyclophosphamide; Mel, melphalan; Bu, busulfan; and ANC, absolute neutrophil count.